First Nebraska Trust Co Takes Position in UnitedHealth Group Incorporated $UNH

Key Points

• First Nebraska Trust Co purchased 4,077 UnitedHealth shares in the first quarter, valued at approximately $1.1 million. Institutional investors collectively own 87.86% of the company.
• UnitedHealth reported quarterly EPS of $6.38, beating estimates of $4.94, while revenue reached $112.03 billion. The company maintained 2026 EPS guidance of $19.50–$20.00 and raised its quarterly dividend to $2.32 per share.
• Analysts remain broadly optimistic, with a consensus “Moderate Buy” rating and an average price target of $455.92, although risks include surprise-billing costs, regulation, Medicaid exposure and Medicare Advantage changes.

First Nebraska Trust Co purchased a new stake in UnitedHealth Group Incorporated (NYSE:UNH - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 4,077 shares of the healthcare conglomerate's stock, valued at approximately $1,103,000.

Other hedge funds have also recently bought and sold shares of the company. Sarver Vrooman Wealth Advisors bought a new stake in shares of UnitedHealth Group during the 4th quarter worth approximately $25,000. Anfield Capital Management LLC raised its position in UnitedHealth Group by 220.0% during the fourth quarter. Anfield Capital Management LLC now owns 80 shares of the healthcare conglomerate's stock valued at $26,000 after purchasing an additional 55 shares in the last quarter. Joseph Group Capital Management acquired a new stake in shares of UnitedHealth Group in the 4th quarter valued at $27,000. Nalls Sherbakoff Group LLC acquired a new position in shares of UnitedHealth Group during the 4th quarter worth $27,000. Finally, Lifetime Wealth Management P.C. bought a new stake in shares of UnitedHealth Group during the 4th quarter worth $29,000. 87.86% of the stock is owned by institutional investors.

UnitedHealth Group News Roundup

Here are the key news stories impacting UnitedHealth Group this week:

• Positive Sentiment: Analysts at Zacks Research raised EPS forecasts for several future periods, including Q3 2026, Q1 2027, Q3 2027, Q4 2027, and Q1 2028. Zacks maintained a “Strong Buy” rating, reinforcing expectations for an earnings recovery.
• Positive Sentiment: Erste Group Bank increased its FY2026 EPS estimate to $19.85 from $18.33 and its FY2027 estimate to $22.44 from $20.87, maintaining a “Buy” rating. MarketBeat UnitedHealth analyst estimates
• Positive Sentiment: Recent coverage highlights UNH’s second-quarter earnings beat, lower medical-cost ratio, improved margins, and raised 2026 guidance as evidence that the company’s turnaround is gaining traction. Its diversified Optum platform and growing use of artificial intelligence are also viewed as longer-term strengths. UnitedHealth turnaround signal
• Positive Sentiment: A separate valuation update lifted the estimated fair value from $424.23 to $475.23, reflecting improved Medicare Advantage and Optum Health assumptions. The average brokerage recommendation remains equivalent to “Buy,” although the usefulness of broadly positive analyst ratings is questioned. UnitedHealth fair value update
• Neutral Sentiment: Commentary says the recent stock advance reflects a Medicare Advantage repricing strategy that management outlined months earlier, suggesting the market is reassessing earnings power rather than responding to a new operational announcement. UnitedHealth Medicare Advantage repricing analysis
• Negative Sentiment: Zacks reduced its Q4 2026 EPS estimate to $2.25 from $2.47 and trimmed its Q2 2028 forecast to $5.84 from $5.92. These isolated cuts may be contributing to caution even as the firm remains bullish overall.
• Negative Sentiment: UnitedHealth faces scrutiny over surprise-billing dispute costs, while broader risks include commercial-market trends, Medicaid exposure, and regulation. Medicare Advantage insurers are also redesigning 2027 plans, potentially affecting enrollment, benefits, and member retention. Cigna and UnitedHealth cost coverage

UnitedHealth Group Trading Down 1.6%

Shares of NYSE UNH opened at $414.82 on Friday. The stock has a market cap of $376.72 billion, a P/E ratio of 26.69, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The firm has a 50 day moving average price of $411.39 and a two-hundred day moving average price of $348.26. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.80 and a current ratio of 0.78. UnitedHealth Group Incorporated has a 52-week low of $234.60 and a 52-week high of $461.62.

UnitedHealth Group (NYSE:UNH - Get Free Report) last issued its quarterly earnings data on Thursday, July 16th. The healthcare conglomerate reported $6.38 earnings per share for the quarter, topping the consensus estimate of $4.94 by $1.44. The company had revenue of $112.03 billion for the quarter, compared to analysts' expectations of $110.81 billion. UnitedHealth Group had a net margin of 3.14% and a return on equity of 16.53%. UnitedHealth Group's revenue for the quarter was up .4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.08 earnings per share. UnitedHealth Group has set its FY 2026 guidance at 19.500-20.000 EPS. As a group, equities analysts forecast that UnitedHealth Group Incorporated will post 19.69 EPS for the current year.

UnitedHealth Group Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Stockholders of record on Monday, June 15th were given a dividend of $2.32 per share. This represents a $9.28 dividend on an annualized basis and a dividend yield of 2.2%. This is a positive change from UnitedHealth Group's previous quarterly dividend of $2.21. The ex-dividend date was Monday, June 15th. UnitedHealth Group's dividend payout ratio is 59.72%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Cantor Fitzgerald reissued an "overweight" rating on shares of UnitedHealth Group in a research note on Thursday, June 11th. Oppenheimer upped their price objective on shares of UnitedHealth Group from $420.00 to $500.00 and gave the stock an "outperform" rating in a research report on Friday, July 17th. DA Davidson set a $512.00 target price on shares of UnitedHealth Group in a research report on Tuesday, July 21st. Bank of America reiterated a "buy" rating on shares of UnitedHealth Group in a report on Monday, July 20th. Finally, HSBC boosted their price objective on UnitedHealth Group from $300.00 to $380.00 and gave the stock a "hold" rating in a research report on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, UnitedHealth Group currently has a consensus rating of "Moderate Buy" and a consensus price target of $455.92.

UnitedHealth Group Profile

UnitedHealth Group Inc is a diversified health care company headquartered in Minnetonka, Minnesota, that operates two primary business platforms: UnitedHealthcare and Optum. Founded in 1977, the company provides a broad range of health benefits and health care services to individuals, employers, governmental entities and other organizations. Its operations span commercial employer-sponsored plans, individual and Medicare and Medicaid programs, and services for customers and health systems in the United States and selected international markets.

UnitedHealthcare is the company's benefits business, administering health plans and networks, managing provider relationships, and offering coverage products for employers, individuals, and government-sponsored programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.